Background and objective: Yellow nail syndrome (YNS) is a rare and poorly described disease process. In this case-control study, clinical features and findings on HRCT were compared with idiopathic bronchiectasis (IBx). 
INTRODUCTION
Yellow nail syndrome (YNS) was initially described by Samman and White in 1964 and the literature currently documents approximately 150 cases. 1 It is a rare clinical syndrome characterized by a triad of yellow dystrophic nails, lymphoedema and pulmonary manifestations. These include chronic cough with sputum, recurrent respiratory infections, pleural effusions, bronchiectasis and rhinosinusitis. It has been previously accepted that two of the triad are adequate for diagnosis. 2 The complete triad occurs in one-third of patients 3 where symptoms may occur years apart. 4 The characteristic nail changes in YNS include yellow-green discolouration, slow growth, cross-ridging, loss of cuticle, over-curvature, onycholysis and shedding. 1 The aetiology of YNS remains undefined; however, the pathogenesis may involve impaired lymphatic drainage. 5 Lymphangiography has shown hypoplastic lymphatic systems in the legs and lungs of some patients. 1, 5 This finding has not been confirmed by lymphoscintigraphic studies and, given the reversibility in some, the underlying cause may be functional rather than anatomical. 5 A small subset has hypoalbuminaemia caused by enteric albumin loss suggesting increased microvascular permeability. 6 The cause of bronchiectasis is unclear but may relate to dysfunctional lymphatics and impaired secretion drainage, with subsequent increased infection risk.
In 2008, Maldonado et al. described 41 patients with YNS (mean age of onset: 61 years). Eighteen patients (44%) had mainly symmetrical lower lobe bronchiectasis. 7 Seventeen (41%) had chronic rhinosinusitis. By
SUMMARY AT A GLANCE
Bronchiectasis in yellow nail syndrome (YNS) has distinct features which influence clinical presentation and management. Bronchiectasis in YNS is milder than in idiopathic bronchiectasis, with less upper and middle lobe disease, but increased mucus plugging. A better understanding of aetiology may influence future research and management decisions.
comparison, a study of 165 consecutive bronchiectasis patients referred to a single centre contained 4 patients with YNS and 43 with IBx. The mean age of onset of IBx was 43 years with female predominance (65%), with a predominantly lower lobe bronchiectasis and chronic rhinosinusitis. 8 Patients with different bronchiectasis aetiologies have characteristic computed tomography (CT) scan appearances and clinical features. This case-control study of patients referred to a tertiary specialty hospital aims to further define the respiratory features of YNS by comparing radiological findings, lung function and microbiology with a matched cohort of IBx patients.
METHODS
YNS patients were identified by electronically searching all Royal Brompton Hospital adult bronchiectasis clinic letters from 2007 to 2013. Patients were initially referred for chronic productive cough with suspected or previously confirmed bronchiectasis, with or without yellow nails. Diagnosis of YNS was made (often subsequently) after the development of yellow nails. Clinical features, microbiology, radiology, lung function, progress and follow-up duration were recorded. All patients had been investigated using a protocol previously published. 8 This includes blood investigations to exclude known aetiologies: nasal nitric oxide as a test for primary ciliary dyskinesia (followed by light and electron microscopy of nasal epithelium if indicated) and sweat test (and/or genotyping) for cystic fibrosis. 8 The study was an anonymized retrospective review of cases and neither patient consent nor ethical approval was sought. All patients attending the Royal Brompton Hospital are informed about the use of patient data for continuing research at the hospital.
IBx patients were defined as having had no history of serious infections predating bronchiectasis, with normal or negative tests for other bronchiectasis aetiologies. 8 The IBx comparison group was formulated by matching IBx patients to YNS patients in a 2:1 ratio, matched for age (within 10 years), duration of symptoms (within 5 years) and, for lung function comparison, gender.
HRCT scans were performed on initial assessment. About 1.5-mm sections were obtained at 10-mm intervals, supine and at full inspiration. Bronchiectasis was defined according to the accepted CT criteria. 9 All CT scans were independently reviewed by the same two experienced observers, blinded to clinical information. Observers awarded scores (grades) per lobe (lingula regarded as a separate lobe) for eight variables: extent of bronchiectasis, severity of bronchial dilation, bronchial wall thickness, mucus plugging, tree-in-bud pattern, mosaicism, consolidation and septal thickening. Full scoring criteria are described in Appendix S1 (Supplementary Information), and are similar to previous studies. 10, 11 After initial scoring, a consensus score was agreed between observers in cases with >1 point discrepancy, where one result was zero, or where there was a >15% discrepancy for mosaicism or consolidation. Consensus scores were used for data analysis. Lung function was compared between diseases, where YNS and IBx patients were also gender-matched (as well as for age and symptom duration). This meant that the matched IBx lung function group and radiology group were not necessarily formed of the same IBx patients. However, matched YNS/IBx patients were kept the same where possible; 28 of the idiopathic patients used for lung function comparison were also used for CT comparison (this meant that there were 16 IBx patients who featured only in the PFT comparison group, and 10 who featured only in the CT comparison group). The YNS group was consistent throughout. The lung function-matched IBx group was the comparator group used to compare microbiology findings between diseases (as opposed the IBx radiology-matched group used for CT comparison). Lung function readings and microbiology data were recorded at initial assessment and at every subsequent visit (in order to record any subsequent Pseudomonas aeruginosa infection). Lung function data were compared using an unpaired Student's t-test. Categorical variables, namely presence or absence of P. aeruginosa, were compared using a chi-square test. A P-value of <0.05 was regarded as being statistically significant.
Statistical analysis

RESULTS
Twenty-five patients with YNS attended clinics at the Royal Brompton Hospital between 2007 and 2013. The median referral age of YNS was 58.2 years (range:
11.8-77.7 years), and median age of first symptoms was 53 years (range: 4-75 years). Twelve patients were males (48%). Twenty-three of the 25 (92%) patients were Caucasian from the UK and Ireland. One patient was from Iraq with Arabic origins and the other was Asian from Sri Lanka. All presented to the Royal Brompton with chronic cough and recurrent infections. During follow-up, 21 patients suffered from chronic sinusitis and 10 had wheeze. Three patients had lymphoedema of lower limbs, one with left arm involvement. Five patients had a history of pleural effusion. YNS and IBx individual patient characteristics are described in more detail in Tables S1 and S2 (Supplementary Information).
Twenty-two of the 25 patients (88%) had abnormal nails at referral, with the remaining 3 patients developing yellow nails within 2 years. In the majority of patients (17, 68%), chest symptoms preceded nail changes. Yellow nails had preceded chest symptoms by 1 year in two patients and occurred simultaneously in six patients. Two patients had a history of malignancy (breast and melanoma), five patients had reflux, four had coronary artery disease and two had cardiac failure. One patient had asbestos plaques. The proportion of ex-smokers was similar between YNS and IBx (32% and 29% respectively). None were current smokers.
Ig levels were normal in all patients. Two patients had lymphopenia (lymphocyte count of 0.7 × 10 9 /L and 1.0 × 10 9 /L). Four patients had low albumin levels of 26-34 g/L. Seven patients had elevated IgE levels (>150 IU/mL). Two of these were diagnosed with Aspergillus sensitivity, with Aspergillus fumigatus RAST results of 14.7 and 9.74 IU/mL. Neither of these patients had peripheral eosinophilia nor clinical/radiological evidence of ABPA.
The median follow-up was 6. 
Microbiology
At initial referral, sputum cultured P. aeruginosa in 5 of 22 YNS patients (23%), Haemophilus influenzae in 5 (23%), Streptococcus pneumoniae in 2 (9%) and Moraxella catarrhalis in 1 patient (5%). Nine (41%) patients had no significant bacterial growth. The initial results were unavailable for three patients. No mycobacteria were cultured. By comparison, 12 of the 44 (27%) IBx patients cultured P. aeruginosa. During follow-up, 9 further YNS and 12 further IBx patients became colonized with P. aeruginosa (64% and 55% of cohort, respectively). There was no significant difference in incidence of P. aeruginosa at presentation (P = 0.69) or during follow up (P = 0.48) between diseases. Comparison of microbiology between diseases is shown in Table 1 .
Lung function studies
Lung function studies showed YNS to be a mildly obstructive lung disease, with no significant difference in readings compared with IBx (Table 2) .
Within the YNS group, patients colonized with P. aeruginosa at presentation had a statistically lower mean FEV1 (P = 0.013) and FVC (P = 0.042) than those without colonization. 
Radiology
Nineteen YNS patients had CT scans available, where seventeen showed bronchiectasis. The remaining two patients scored zero for extent and severity of bronchiectasis. However, both had bronchial wall thickening, chronic daily sputum production and recurrent infections, with bronchiectasis diagnosed clinically. One patient's CT scan had been reported as mild bilateral lower lobe bronchiectasis by the radiologist reporting it originally; the second patient had right lower lobe bronchiectasis on a repeat scan 2 years later. YNS patients had significantly lower extent (P = 0.04), severity (P = 0.03) and bronchial wall thickness (P = 0.05) scores than matched IBx patients (see Table 3 ). Differences in scores for tree-in-bud, mosaicism and mucus plugging did not reach statistical significance on initial analysis (Wilcoxon signed-rank test). Consolidation was present in only 4 of 19 (21%) YNS and 13 of 38 (34%) IBx patients. Septal thickening was present in only 6 of 19 (32%) YNS and 13 of 38 (34%) IBx patients. Median global scores for consolidation and septal thickening were zero, so they were not included in Table 3 .
Examination of a stepwise logistic regression model (with the HRCT variables listed in Table 3 examined as initial covariates prior to stepwise evaluation) showed that when compared with IBx, YNS was independently associated with less bronchial wall thickness (OR: 0.64; 95% CI: 0.46-0.87; P < 0.005) and higher mucus plugging scores (OR: 1.89; 95% CI: 1.10-3.25; P = 0.02) than IBx. Analyses of the distribution of abnormalities on HRCT revealed that when compared with IBx, YNS was characterized by lower scores for the extent and severity of bronchiectasis and overall bronchial wall thickness (all P < 0.05). However, lower lobe scores taken in isolation did not differ between the two diseases for any HRCT variable. Thus, compared with IBx, YNS is associated with sparing of the upper and middle lobes, with the abnormalities being present in the lower lobes.
Management
All patients received physiotherapy tuition at presentation and throughout follow-up. Low-dose antibiotic prophylaxis was introduced in 20 (80%) YNS patients because of poor symptom control and/or four exacerbations or more per year. Three of these stopped antibiotics due to intolerance, side effects or non-response, leaving 17 on long-term prophylaxis. Prophylaxis was oral azithromycin in 14 of 17 patients (82%) (usually 250 mg three times weekly). This improved chest symptoms in the majority (9/14 = 64%) of this group. One patient colonized with P. aeruginosa was taking colomycin nebulizers additionally as dual prophylaxis. Three of the 17 patients took other forms of antibiotic prophylaxis; 2 took colomycin alone (intolerant to azithromycin) with improvement in symptoms and one on regular erythromycin had no improvement. For the YNS group as a whole, 16 (64%) had a subjective improvement in chest symptoms since first review. Eleven of these were taking regular antibiotic prophylaxis and five patients improved with physiotherapy alone. A CT scan of a YNS patient before and after treatment with a long course of clarithromycin 250 mg bd and inhaled colomycin 1 million units bd, started when Pseudomonas was isolated, is shown in Figure 1 .
Twenty-three of the 25 patients had persisting nail changes at the time of last review, where 17 had improved over time. Seven of these also had improved chest symptoms over time. Resolution of nail changes occurred in two patients with improvement in chest symptoms (complete resolution in one). An example of a patient's nail changes before and after treatment with physiotherapy and episodic antibiotics during infective exacerbations is shown in Figure 2 . 
0.04
Severity of bronchiectasis (24) 5.5 (0-13.5)
0.03
Wall thickness (24) 5.5 (1-13) 6.5 (1-17) 
0.05
Tree-in-bud (12) 2.5 (0 
DISCUSSION
This study investigates YNS patients referred to a tertiary hospital respiratory clinic, and compares them to matched IBx patients. IBx was chosen as the comparator group because both groups have normal or negative tests for other aetiologies, present in a similar way and are currently only differentiated by nail changes. A better understanding of aetiology may influence future research and management decisions. A recent multicentre study of 1258 bronchiectasis patients determined the aetiology in 60%, where this knowledge changed the patient's management in 13% of cases. 12 Additionally, the radiological and clinical findings in YNS bronchiectasis have been poorly defined. In Varney et al.'s series of 17 YNS patients, all had chronic cough and the majority had rhinosinusitis (83%). 13 Lymphoedema was present in 76%, compared to only 36% with lymphatic dysfunction in our series. Hoque et al. described 11 YNS patients of whom only six had bronchiectasis.
14 Comparable with our cohort, the mean age of onset of symptoms was 53 years (range: 27-69 years) but in contrast they reported lymphoedema in 46% of patients and only 27% had sinusitis. A recent study of 165 consecutive bronchiectasis patients (43 with IBx) found that the average age of onset of IBx was 43 years with 65% female predominance. 8 Other studies have shown similar younger age of onset for IBx and female predominance. 15, 16 In our YNS cohort, the average age of onset was 53 years, with no gender predominance.
YNS has been associated with other conditions including autoimmune disorders, 4 immunodeficiency states, 17, 18 nephrotic syndrome, 19 Guillain-Barre syndrome, 20 drugs (D-penicillamine, gold) and cancers. 4, 6, 17, 19, [21] [22] [23] [24] [25] [26] [27] [28] Three of our patients had a history of malignancy. YNS has also been reportedly associated with lymphopenia, low IgA levels and hypogammaglobulinaemia. 29 Two patients in our series had lymphopenia but Ig levels were normal in all. These previously described associations of YNS were therefore not seen in our cohort of patients presenting to a chest clinic.
The notable CT finding of YNS in our study was symmetrical predominantly lower lobe bronchiectasis, with significantly less upper and middle lobe disease, and increased mucus plugging compared with IBx. Our cohort of YNS patients had significantly milder disease than IBx in terms of total extent, severity and bronchial wall thickening. However, this may be explained by disease being restricted to the lower lobes in YNS. We therefore hypothesize that bronchiectasis in YNS is a disorder of delayed mucociliary clearance due to abnormal lymphatic structure/function, where gravity influences lower lobe disease development. However, other factors such as frequency and severity of infections and the presence of other pro-inflammatory influences (such as Aspergillus sensitivity in two patients) will also determine bronchiectasis development. Previous CT findings in YNS include one case series of four patients all with bronchiectasis primarily in the middle lobe, lingula and lower lobe. 30 Maldonado et al. reported 41 YNS patients, of whom 18 had bilateral lower lobe bronchiectasis on CT scan. 7 A possible explanation for milder disease in YNS could be earlier referral (and therefore treatment) due to yellow nail development. This explanation is however unlikely because YNS and IBx patients were matched by length of symptoms at the time of CT/lung function tests.
The YNS group as a whole had mild abnormalities of lung function, although patients with P. aeruginosa had significantly poorer FEV1 readings at presentation Yellow nail syndrome and bronchiectasis (P = 0.013). The association of P. aeruginosa with more severe airflow limitation has been noted in bronchiectasis previously. 31, 32 Lung function was comparable to the IBx cohort, as was incidence of P. aeruginosa both at presentation and subsequently. This was surprising considering less severe and less widespread bronchiectasis in YNS. One explanation could be increased mucus plugging predisposing to bacterial colonization or possibly higher use of antibiotic prophylaxis in this group.
Long-term prophylaxis with azithromycin improved chest symptoms (cough, sputum and exacerbation frequency) in the majority (64%) of the YNS cohort taking it. This suggests that it is a good choice where symptom control is poor with physiotherapy and rescue antibiotics. Improvement with clarithromycin has been described in two case studies of YNS. 33, 34 However, one study focused on nail improvement, whilst the second described a case of eosinophilic bronchial disease in YNS, unlike in our cohort.
There are some limitations to our study. YNS and IBx cohorts were matched for age and length of symptoms, therefore patient recollection was used to determine symptom onset date. The use of a small (5-year) margin attempts to minimize poor recollection or individual variability in perception of symptoms. There may be some patient selection bias, as YNS patients may be referred earlier due to yellow nails rather than for problematic respiratory symptoms. However, the majority of YNS patients in our cohort were undiagnosed at referral. This study did not assess disease improvement objectively, and relied on clinic letter reports of symptoms. This is a small cohort of patients, as YNS is rare and we are a single centre. However, being a tertiary respiratory centre has enabled us to match IBx patients
In conclusion, this study shows YNS as a distinct aetiology of bronchiectasis that may relate to impaired mucus clearance. The bronchiectasis in YNS is usually mild and involves predominantly lower lobes, often presenting at an older age than IBx. Management should target mucus clearance. Long-term macrolide antibiotics may provide symptomatic relief, and in some patients led to resolution of dystrophic nails. Patients should be screened for impaired immunity, Aspergillus sensitivity and malignancy, although these findings were uncommon in our cohort.
